Loading...
Loading...
INCY| Name | Value |
|---|---|
| Revenues | 1,043.8M |
| Cost of Revenue | 93.0M |
| Gross Profit | 950.8M |
| Operating Expense | 1,428.0M |
| Operating I/L | -477.2M |
| Other Income/Expense | 88.4M |
| Interest Income | 49.8M |
| Pretax | -389.8M |
| Income Tax Expense | 54.8M |
| Net Income/Loss | -444.6M |
Incyte Corporation is a biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics globally. The company's key products include JAKAFI for myelofibrosis and polycythemia vera, PEMAZYRE for various tumor types, and ICLUSIG for leukemia treatment. Its clinical stage products encompass treatments for chronic graft-versus-host-diseases, bladder cancer, and lymphomas. Incyte also engages in collaboration agreements with several pharmaceutical companies for research and development. The company generates revenue through the sale of its proprietary drugs and through collaboration agreements with other pharmaceutical companies.
